CTI Biopharma Corp. said institutional investors will purchase 10 million shares of the Seattle-based company's common stock in a registered direct offering conducted without an underwriter or placement agent for gross proceeds to the company of about $15.7 million at a purchase price per share of $1.57. Net proceeds from the offering are expected to hit $15.1 million.